Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018461 | 0.80 | SSTR4 (0.42) | NAMPTGPR119RAB9ASSTR4GRM2 | |
| SCHEMBL12578615 | 0.79 | SLC6A2 (0.35) | NAMPTSSTR4GRM2CPB2 | |
| SCHEMBL17018568 | 0.76 | SSTR4 (0.34) | NAMPTRAB9ASSTR4GRM2CPB2 | |
| SCHEMBL12578613 | 0.75 | TSPO (0.44) | GPR119 | |
| SCHEMBL12578609 | 0.74 | CA12 (0.38) | SSTR4GRM2 | |
| SCHEMBL17018592 | 0.74 | GUCY1B2 (0.35) | NAMPTGPR119SSTR4GRM2CPB2 | |
| SCHEMBL30400038 | 0.72 | CYP17A1 (0.46) | GPR119RAB9ASSTR4GRM2CPB2 | |
| SCHEMBL31407149 | 0.69 | GPR119 (0.33) | NAMPTGPR119 | |
| SCHEMBL12386820 | 0.69 | GPR119 (0.37) | GPR119RAB9ASSTR4GRM2CPB2 | |
| SCHEMBL31407263 | 0.69 | SSTR4 (0.41) | NAMPTGPR119SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | NAMPT 2102/4885GPR119 880/4885RAB9A 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.